Euroz Hartleys Healthcare Research Analyst Seth Lizee recently spoke with Professor Jonathan Barratt, a recognised global expert in rare kidney disease, to discuss Focal Segmental Glomerulosclerosis (FSGS) – a rare, progressive condition that causes scarring in the kidney’s filtering units and can ultimately lead to kidney failure and death.
The discussion comes at an important time, as ASX-listed Dimerix (DXB) advances DMX-200, its lead therapy for FSGS, through a global Phase 3 clinical trial. Interim results are anticipated later this year or early next year and may potential provide a pathway toward accelerated approval.
Timestamps:
- Introduction and Background in Rare Kidney Diseases (1:25 - 2:47)
- Focal segmental glomerulosclerosis: Unmet Needs and the Drive for Better Treatments (2:48 - 4:47)
- Proteinuria as a Surrogate Endpoint: Clinician Perspectives (4:48 - 11:05)
- Emerging FSGS Therapies: Potential Place in Clinical Practice (11:06 - 14:47)
Seth Lizee
Research Analyst
+61 8 9488 1414
slizee@eurozhartleys.com
Seth is a Research Analyst with 7 years’ experience focused on small to mid-cap ASX-listed healthcare companies.
Seth holds a Bachelor of Commerce (BCom) from the University of Western Australia.
Professor Jonathan Barratt
Professor Jonathan Barratt leads the Renal Research Group within the College of Life Sciences at the University of Leicester, where his laboratory investigates a range of rare kidney diseases. He is actively involved in both early- and late-phase clinical trials in kidney disease and is a member of the KDIGO (Kidney Disease: Improving Global Outcomes) group, which develops international guidelines for kidney care. He also runs weekly clinics seeing patients with a wide spectrum of rare kidney disorders, including FSGS.
